ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
112 N Bayshore Blvd #3 San Mateo, Ca 94401
650-544-0793
jamesfgraham111@gmail.com
Copyright © 2024 botnik. All Rights Reserved
